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Purpose: To investigate the accuracy of a TrueBeam VirtuaLinac system for beam commissioning and 
dose calculation in clinical treatment plans for 6 MV flattened and flattening-filter-free beams.  
Methods: The TrueBeam VirtuaLinac system was configured to simulate the IAEA phase space data 
(PSD) outside the gantry head (z=58 cm) for different field sizes. DOSXYZnrc software was used to 
simulate the water phantom and calculate dose. The beam commissioning data included (1) beam profiles 
along the x-axis and the diagonal direction, (2) percentage depth dose, (3) output factor. Savitzky-Golay 
(SG) filters were applied to process the calculated Monte-Carlo (MC) simulation data. MC simulation 
results were benchmarked with the clinical golden data. Varian Eclipse treatment planning system was 
commissioned based on the processed MC data (MC plan) and the clinical golden data (control plan). 
Head & neck and lung cancer cases were used to investigate the differences in dose distribution in both 
static intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) plans. 
Dose volume histograms (DVHs) were used for analysis.  
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Results: For beam profiles, 100% gamma passing rate was obtained for the dose in the field region. The 
maximum averaged deviation in the penumbra region was 2.75 mm for a flattened beam of           
field size. The flatting filter free (FFF) beam with           field size at 30 cm depth showed a 
deviation of 3.06 mm. Maximum deviations (>2%) were observed for the diagonal beam profiles 
(          field size) at 30 cm depth. The MC simulation underestimated the dose in the tail region by 
3.1% and 2.3% for flattened and FFF beams, respectively. For PDD, the gamma passing rate was near 
99%. Large deviations (>2%) were observed at the surface of water phantom. All the deviations for the 
output factors were within the 2% of threshold value. For clinical IMRT plans (both static IMRT and 
VMAT), good agreement (<1 Gy in mean and maximum dose) was obtained between the MC plans and 
the control plans for all organs in the FFF MC plans, and for most of the organs in the flattened MC plans. 
Large deviations ( 1 Gy) were observed in a lung case for the flattened static IMRT plans in skin and 
PTV66. For skin, the absolute deviations were 0.78 Gy and 1.28 Gy for mean and maximum doses, 
respectively. For PTV66, the absolute deviations were 0.16 Gy and 1.25 Gy for mean and maximum 
doses, respectively. 
Conclusions: Compared to the flattened beam, the MC plans of the FFF beam showed lower deviations 
in mean and maximum doses compared to the control plans.  Overall, we demonstrated that the beam 
commissioning using the TrueBeam VirtuaLinac system can provide accurate dose calculation as the 
clinical golden data. 
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1. INTRODUCTION 
 
In recent decades simulation with Monte-Carlo (MC) techniques has been widely used to estimate the 
accurate dose distribution for clinical radiotherapy. The simulation of a beam spectrum requires 
geometrical configuration of the hardware in the head of the machine. However, this information is often 
not available to the research community due to the commercial interest of the manufacturer. In order to 
overcome this difficulty, phase space data (PSD) is usually used as a virtual source to simulate the 
complex hardware. The PSD records the representative pseudo-particles generated during the 
radiotherapy (RT) process taking into consideration the position, direction, energy and the statistical 
weight for each particle. The International Atomic Energy Agency (IAEA) promoted a PSD format to 
facilitate the interchange of phase space files between different Monte Carlo codes
1.
  
In recent years, Varian released a new class of linear accelerator referred to as the TrueBeam (TB) linear 
accelerator (linac) system (Varian Medical Systems, Palo Alto, California). In this system, the gantry 
head is completely redesigned. One of the important characteristics of the TB system is its flattening-
filter-free (FFF) operation in the photon beam mode. Compared to the conventional flattened beam, the 
FFF beam has several advantages, including higher dose rate
2-5
, comparatively less external scatter from 
the gantry head
6-8
, lower neutron contamination for high energy beams (>10 MV)
9-11 and improved 
calculation accuracy due to the removal of the flattening filter
2
.  
In order to simulate the TB system, Constantin et al
12-13
 developed a technique to link the computer-aided 
design (CAD) of the hardware system to the Geant4
14
 based MC simulation. The IAEA PSD for the 
geometry above the jaws of the TB system was released by Varian Medical System. Varian also 
developed a cloud-based web interface, called ―VirtuaLinac‖.  Compared to the self-developed MC model, 
the VirtuaLinac system has the components below the jaws which are not part of the data package (e.g. 
the jaws and the baseplate). 
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Several groups investigated the characteristics of the FFF beam based on the MC simulation technique
15-18
. 
Belosi et al investigated the accuracy of the IAEA PSD for the geometry above the jaws using the 
geometry of a Clinac 2100 C/D and compared the MC simulation results to measurement data
19
. Parsons 
et al investigated the low-Z target image quality based on the VirtuaLinac system
20
.  Gete et al compared 
the differences between the VMAT plans based on MC and Eclipse treatment planning system
21
. The 
accuracy of the clinical intensity-modulated-radiotherapy (IMRT) plans using beam commissioning data 
of the VirtuaLinac system is still unclear. In this manuscript, we investigated the accuracy of the PSD in 
the VirtuaLinac system for beam commissioning and IMRT plans.  
 
2. MATERIALS AND METHODS 
2.1. MC simulation of the TB system 
In our study, the MC simulation of the TB system consisted of two key steps. In step one, the IAEA PSD 
released by Varian was uploaded to the VirtuaLinac system. We defined the target at Z = 0 and the iso-
center of the TB system at Z = 100 cm. The arc scoring plane of the original PSD was at Z=26.7 cm, 
above the jaws of the TB system. New PSD was calculated using the VirtuaLinac system. The scoring 
plane of the new PSD was at Z = 58 cm, just outside the gantry head. In the second step, the PSD (Z = 58 
cm) was input into the DOSXYZnrc software
22
 as a virtual source to simulate the bremsstrahlung photon 
beam from the gantry head. A water phantom was built based on the DOSXYZnrc MC software.    
2.2. Important parameters of the MC simulation 
For the MC simulation, the cut-off energies for photons and electrons were set as, PCUT=0.01 MeV and 
ECUT=0.7 MeV, respectively. Non-uniform voxel sizes were used to calculate the 3D dose matrix. For 
the depths shallower than     , the voxel size was            . For depth deeper than      , 
the voxel size was             . The number of histories (NCASE) to track each particle was 
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      for simulations of all field sizes. For beam profile and percentage-depth-dose (PDD) calculations, 
the source-to-surface-distance (SSD) was 100 cm. For the output factor calculations, the SSD was 95 cm 
and the depth of calculation was 5 cm.  
2.3. Post processing of the MC simulation data 
It is understood that the statistical noise in the MC simulation leads to variations in the calculation results. 
These variations also influence the choice of the dimension of the dose voxel. If the voxel size is too 
small (e.g. 1 mm in the in-plane direction), it will lead to a higher calculation imprecision due to the 
variation in energy deposition from the scattered electrons. Also, the dimension of the dose voxel size is 
limited by the computer memory. In order to overcome these difficulties, an in-house Fortran code was 
developed to process the 3D dose matrix of the MC simulation. The Fortran code had three functions. (1) 
It automatically extracted the data from the 3D dose matrix file generated by the DOSXYZnrc software. 
(2) Based on the polynomial interpolation algorithm
23
, it resampled the beam profile and the PDD of the 
MC simulation with a fine pixel grid (1 mm in all three directions). (3) It smoothed the MC simulation 
data based on the 1D Savitzky-Golay (SG) filter
24
. A 2D SG filter using the Matlab
TM
 (MathWorks, 
Natick, MA, USA) was applied to further reduce the variations in the output factor table
25
.  
 
2.4. Benchmarking the MC simulation 
All of the MC simulation results were benchmarked to the standard clinical golden data
26
. Gamma index
27 
was used to evaluate the deviation between the MC simulation and the golden data for beam profiles, and 
PDDs. The reference field sizes were    ,    ,    ,    ,      ,      ,      , and 
          for beam profiles and PDDs. For beam profiles, the reference depths were 1.5, 5, 10, 20, 
and 30 cm. Three regions were defined for each beam profile and they are summarized as follows: 
6 
 
1. Field region: region within 80% of the field size for field sizes           and within 60% of the 
field sizes for other smaller field sizes (          ). 
2. Penumbra region: off-axis region between 20% and 80% dose lines. 
3. Tail region: off-axis region below the 20% dose line. 
For output factor, the jaws in   and   directions changed from 3 to 40 cm, independently. In total, 81 field 
sizes were calculated to get the output factor table. Relative deviation ( ) of the output factors between 
the MC results and the golden data was calculated.   is defined as 
  
|        |
   
     .  (1) 
In Eq. (1),     and      refer to output factors of standard clinical golden data and MC simulation, 
respectively. 
2.5. IMRT plans evaluation 
The TB 
 
linac system (Varian Medical Systems, Palo Alto, CA) was commissioned on the Eclipse
TM
 
treatment planning system (TPS) based on clinical golden data and the MC simulation data. An 
Anisotropic-Analytical-Algorithm (AAA) was used to calculate the volume dose distribution for both 
static IMRT and VMAT plans. The beam energy was 6 MV and dose grid was 2.5 mm for all treatment 
plans. High definition 120 leaf multi-leaf collimator (MLC) (2.5 mm width in the center and 5 mm width 
in the peripheral) was used to simulate the treatment plans for all cases.  
Head & neck and lung cancer cases were used to investigate the differences in dose distribution in both 
static IMRT (sliding window) and VMAT plans. These two sites were picked due to their larger treated 
areas and large number of organs at risk (OAR) requiring complex treatment planning. For the head & 
neck case (case #1), the dose prescription was 60 Gy in 30 fractions. Two planning-target-volumes (PTVs) 
were used for plan optimization, PTV60 and PTV 54. The field sizes of the treatment were          . 
For the lung case (case #2), the dose prescription was 66 Gy in 33 fractions. The patient had two PTVs, 
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PTV66 and PTV54. The field sizes were          . Both the cases were planned for a uniform dose to 
the target and a minimum dose to the OARs. For all the treatment plans, the dose in the target was 
normalized so that 95% of the primary PTV was covered by the 95% isodose line. Dose constraints to 
OAR’s for two clinical cases are summarized in Table 1. Eight treatment plans were generated using the 
clinical golden data (4 control plans) and the MC simulation data (4 MC plans). For both control and MC 
plans, it contained flattened and FFF static IMRT plans, and flattened and FFF VMAT plans. The MC 
plans utilized the same beam fluence and optimization parameters (e.g. arc number, iso-center position, 
beam angle, etc.) as the corresponding control plans in order to exclude the differences caused by 
different optimizations. A Matlab code based on the CERR
28 was used to extract the dose distribution and 
statistically analyze the results from the DICOM data exported from the Eclipse system. Dose evaluation 
parameters (e.g. mean dose, maximum dose, and organ volume) were benchmarked with the commercial 
Eclipse treatment planning system. Accurate agreements were obtained for all treatment plans. DVH were 
used to evaluate the differences between the control plans and the MC plans in terms of target coverage 
and dose sparing to OAR. 
3. RESULTS 
3.1. Beam profiles along   axis 
The beam profiles of the 6 MV flattened and the FFF beams were benchmarked with the clinical golden 
data. The results are shown in Fig.1. We evaluated the deviations between the clinical golden data and the 
MC simulation in the field region and the penumbra region (defined above). The gamma index ( ) 
analysis
27 in the field region is shown in Table 2. The   values were averaged for all reference depths with 
each field size. The   passing rates were calculated as the fraction of   values which were not greater than 
1. For all field sizes, it is evident that both flattened and FFF beams had 100%   passing rate for both   
index criteria (2 mm/2% and 3 mm/2%), indicating excellent agreements for the beam profiles in the field 
region.  
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The spatial absolute deviations (  ) in the penumbra region between the MC and the clinical golden data 
are shown in Table 3. The    was averaged for all reference depths with each field size. Maximum    
for the flattened and FFF beams, was 2.75 mm (for           field size),  and 3.05 mm (for    
       field size), respectively. 
 
Table 1. The dose constraints to OARs of case #1 and #2 for the normalized DVH. 
 
      
Case #1 
Organ Volume (%) Dose (Gy) Maximum Dose (Gy) 
Left eye N/A N/A 4 
Right eye N/A N/A 4 
Cord+3 mm N/A N/A 43 
Normal N/A N/A 43 
Brain N/A N/A 45 
Right shoulder N/A N/A 5 
Right submandibular N/A N/A 26 
Case #2 
Cord expand N/A N/A 40 
Bilateral lungs-PTV 
25 17.5 N/A 
10 30 N/A 
Heart 40 30 N/A 
Esophagus 40 40 N/A 
Normal N/A N/A 30 
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Figure 1. Beam profile for the 6 MV flattened beam (left column) and 6 MV FFF beam (right column).   
The reference depths are 1.5 cm ((a) and (f)), 5 cm ((b) and (g), 10 cm ((c) and (h)), 20 cm ((d) and (i)), 
30 cm ((e) and (j)). The solid lines represent the clinical golden data and the dashed lines represent the 
MC simulation data. 
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Figure 2. Diagonal beam profile for the 6 MV flattened beam (left column) and 6 MV FFF beam (right 
column).  The field size is          . The reference depths are 1.5 cm ((a) and (f)), 5 cm ((b) and (g)), 
10 cm ((c) and (h)), 20 cm ((d) ,and (i)), 30 cm ((e), and (j)). The blue solid lines represent the clinical 
golden data and the red dashed lines represent the MC simulation data. 
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3.2. Beam profiles along the diagonal direction 
The beam profiles along the diagonal direction (          field size) are shown in Fig. 2 for flattened 
and FFF beams. The   index for the field region and the deviation in the penumbra region (      ) are 
shown in Table 4. For the two selected criteria, the   index of both flattened and FFF beams reached a 
100% passing rate. In the analysis of penumbra, the averaged        were 1.96 mm and 2.14 mm for 
flattened and FFF beams, respectively. Good agreements were obtained between the MC simulation and 
the golden data for most of the results. Deviations were observed in the tail region of the beam profiles 
for           at       depth for both flattened and FFF beams. The maximum dose deviations were 
3.1% and 2.3% for flattened and FFF beams, respectively. Based on previous discussion and literature 
review
13
, the deviations in the tail region may be due to the statistical imprecision in the   and   
coordinates of the electron PSD generated by the Parmela simulation of the TB hardware system.  
3.3. PDD 
MC simulations of the PDDs of selected field sizes are shown in Fig. 3 for both flattened and FFF beams. 
The   index analysis is shown in Table 5. For all reference field sizes, the   index passing rates were 
around 99%. For most of data point, the maximum deviations between the MC simulation and the golden 
data were less than 1%. For the dose at the surface of the water phantom, relatively large deviations (>2%) 
were obtained between the MC results and the golden data. This is due to the steep gradient of the PDD 
curve in the build-up region at the superficial depth of the water phantom. .  
3.4. Output factor 
The relative deviations ( ) of the output factors for 81 field sizes of flattened and FFF beams are shown in 
Fig. 4. These deviations were within 2% for all field sizes. Large deviations (>1.5%) were observed for 
large asymmetric field sizes (e.g.         ).  
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Figure 3. PDD of the 6 MV flattened (left column) and FFF (right column) beams. The SSD is      . 
The field sizes are:          ((a) and (e)),            ((b) and (f)),            ((c) and (g)), and 
           ((d) and (h)).  
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Figure 4. The relative deviations of the output factors for the 6 MV (a) flattened, and (b) FFF beam 
between the MC simulation and the clinical golden data. 
 
Table 2. γ index analysis in the field region of the beam profiles for the 6 MV flattened and the FFF 
beams.  
                  
γ Index of the Beam Profile  
  6 MV Flattened Beam 6 MV FFF Beam 
  2 mm/2% 3 mm/2% 2 mm/2% 3 mm/2% 
Field size  
(cm
2
) γ 
Passing  
Rate (%) Γ 
Passing  
Rate (%) γ 
Passing  
Rate 
(%) γ 
Passing  
Rate (%) 
3x3 0.10 100.0 0.07 100.0 0.11 100.0 0.07 100.0 
4x4 0.17 100.0 0.11 100.0 0.17 100.0 0.11 100.0 
6x6 0.12 100.0 0.08 100.0 0.12 100.0 0.08 100.0 
8x8 0.17 100.0 0.11 100.0 0.17 100.0 0.12 100.0 
10x10 0.15 100.0 0.12 100.0 0.14 100.0 0.10 100.0 
20x20 0.15 100.0 0.11 100.0 0.14 100.0 0.10 100.0 
30x30 0.16 100.0 0.12 100.0 0.14 100.0 0.10 100.0 
40x40 0.18 100.0 0.14 100.0 0.18 100.0 0.15 100.0 
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Table 3. The absolute penumbra deviation between the golden data and the MC simulation. 
      
   (mm) 
Field Size (cm
2
) 6 MV Flattened Beam 6 MV FFF Beam 
3x3 0.48 0.62 
4x4 0.36 0.39 
6x6 0.46 0.48 
8x8 0.75 0.66 
10x10 0.60 0.54 
20x20 1.19 2.59 
30x30 1.36 3.05 
40x40 2.75 1.63 
 
Table 4. γ index analysis in the field region and absolute penumbra deviations of the diagonal beam 
profiles for the 6 MV flattened and FFF beam. The field size is          .  
                
γ Index of the Diagonal Beam Profile 
6 MV Flattened Beam 6 MV FFF Beam 
2 mm/2% 3 mm/2% 2 mm/2% 3 mm/2% 
γ 
Passing 
Rate (%) 
γ 
Passing 
Rate (%) 
γ 
Passing 
Rate (%) 
γ 
Passing 
Rate (%) 
0.2 100 0.19 100 0.21 100 0.18 100 
       (mm) 
6 MV Flattened Beam 6 MV FFF Beam 
1.96 2.14 
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Table 5. Gamma index analysis of the PDD for the 6 MV flattened and FFF beam.  
                  
γ index of the PDD 
  6 MV Flattened Beam 6 MV FFF Beam 
  2 mm/2% 3 mm/2% 2 mm/2% 3 mm/2% 
Field size  
(cm
2
) γ 
Passing  
Rate (%) Γ 
Passing  
Rate (%) γ 
Passing  
Rate 
(%) γ 
Passing  
Rate (%) 
3x3 0.23 99.0 0.20 99.0 0.32 99.0 0.29 99.0 
4x4 0.26 98.7 0.22 98.9 0.32 99.3 0.29 99.3 
6x6 0.30 99.1 0.26 99.1 0.43 98.9 0.40 98.9 
8x8 0.21 98.9 0.17 99.0 0.40 99.1 0.37 99.1 
10x10 0.29 99.0 0.26 99.1 0.45 99.6 0.42 99.6 
20x20 0.26 99.3 0.23 99.3 0.39 99.1 0.36 99.1 
30x30 0.32 99.4 0.29 99.4 0.40 99.3 0.37 99.4 
40x40 0.29 99.3 0.26 99.4 0.45 99.3 0.42 99.4 
 
 
3.5. Clinical IMRT plans’ evaluation 
DVHs of control and MC plans are shown in Fig.6 and Fig.7. The MC plans are in good agreement with 
the control plans for both static IMRT and VMAT plans. For both cases, the FFF beam MC plans 
provided accurate simulation as the control plans (<0.5 Gy for mean dose and maximum dose) for all 
organs for both static IMRT and VMAT plans. Compared to the FFF beam MC plans, the flattened beam 
MC plans showed relatively larger deviations from the control plans. In case #1, for the flattened beam 
plans, as shown in Fig.6 (a) and (c), the skin had the maximum deviation in the static IMRT plan. The 
absolute deviations in mean and maximum dose for skin reached up to 0.34 Gy and 0.61 Gy, respectively. 
In case #2, for flattened beam plans, as shown in Fig. 7 (a), relatively important differences between the 
MC and the control plans were observed in the static IMRT plans for skin and PTV66. For skin, the 
deviations were 0.78 Gy and 1.28 Gy for mean dose and maximum dose, respectively. For PTV66, the 
deviations were 0.16 Gy and 1.25 Gy for mean and maximum dose, respectively. For all other organs in 
Fig. 7 (a), the deviations were less than 0.5 Gy for both mean and maximum doses. For VMAT plans, as 
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shown in Fig.7 (c), the larynx had the maximum dose deviation. The difference was 0.36 Gy for both 
mean and maximum doses. Overall, no clinically significant differences were noticed.  
 
Figure 6. DVH of case #1 (head & neck case) of (a) flattened static IMRT, (b) FFF static IMRT, (c) 
flattened VMAT, and (d) FFF VMAT plans. The solid lines represent the control plans and the dashed 
lines represent the MC plans.  
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Figure 7. DVH of case #2 (lung case) of (a) flattened static IMRT, (b) FFF static IMRT, (c) flattened 
VMAT, and (d) FFF VMAT plans. The solid lines represent the control plans and the dashed lines 
represent the MC plans.  
 
4. DISCUSSION 
Based on Fig.6 and Fig.7, the FFF beam contributed to improved dose calculation accuracy in the clinical 
IMRT plans compared to the flattened beam. The higher deviations between the MC plans and the control 
plans for the flattened beam can possibly be explained by the higher statistical imprecisions in the output 
factor for the flattened beam. Based on Fig.4, compared to the FFF beam, the output factor of the 
flattened beam shows larger deviations to the clinical golden data. The mean value of   for the FFF beam 
is 0.74%. For the flattened beam, this value reaches 0.80%. In addition, the FFF beam shows lower 
variations in the output factor compared to the flattened beam
2
. These two effects possibly contribute to 
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the improved dose calculation accuracy of the FFF beam in clinical treatment plans compared to the 
flattened beam. . 
It is easy to modify and design new hardware components of the TB system based on the VirtuaLinac MC 
model. How accurate is the MC simulation in the clinical treatment plan calculation is an open question. 
In this manuscript, we evaluated the accuracy of the entire chain of phase space files generated by the 
VirtuaLinac system in clinical plans. In addition, beam commissioning data of the VirtuaLinac system 
may be used to supplement directly measured data. The relative magnitude of agreement between MC and 
golden beam data presented in this research may assist a physicist in terms of the percent dose deviation 
that one may expect when using MC data for verification purposes.  
5. CONCLUSIONS 
In this manuscript, we investigated the accuracy of the 6 MV flattened and FFF beams of the VirtuaLinac 
system in terms of beam commissioning and clinical IMRT treatment plans. Good agreement was 
obtained between the MC simulation and the clinical golden data for both flattened and FFF beams. For 
beam commissioning, the maximum deviations between the MC simulation and the golden data were 
observed in the diagonal beam profile (          field size) at 30 cm depth. The MC simulation 
underestimated the dose in the tail region of the beam profile up to 3.1% and 2.3% for flattened and FFF 
beams, respectively. For clinical applications, the MC FFF beam plans showed lower deviations to the 
control plans compared to the MC flattened beam plans.  These deviations are not clinically significant 
and hence demonstrate the acceptability of the VirtuaLinac system. Based on our finding we believe it 
can be used for other treatment sites successfully. Overall, the presented study demonstrated that dose 
calculation using the beam commissioning data of the VirtuaLinac system can provide accurate 
simulations for the clinical IMRT (including static IMRT and VMAT) treatment plan calculations. 
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